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Abstract
Several lines of evidence linkmacrophage activation and inflammationwith (monoaminergic) ner-
vous systems in the etiology of depression. IFN treatment is associated with depressive symp-
toms, whereas anti-TNF𝛼 therapies elicit positive mood. This study describes the actions of
2 monoaminergic antidepressants (escitalopram, nortriptyline) and 3 anti-inflammatory drugs
(indomethacin, prednisolone, and anti-TNF𝛼 antibody) on the response of human monocyte-
derived macrophages (MDMs) from 6 individuals to LPS or IFN-𝛼. Expression profiling revealed
robust changes in the MDM transcriptome (3294 genes at P < 0.001) following LPS challenge,
whereas a more limited subset of genes (499) responded to IFN𝛼. Contrary to published reports,
administered at nontoxic doses, neither monoaminergic antidepressant significantly modulated
the transcriptional response to either inflammatory challenge. Each anti-inflammatory drug had
a distinct impact on the expression of inflammatory cytokines and on the profile of inducible
gene expression—notably on the regulation of enzymes involved in metabolism of tryptophan.
Inter alia, the effect of anti-TNF𝛼 antibody confirmed a predicted autocrine stimulatory loop in
human macrophages. The transcriptional changes were predictive of tryptophan availability and
kynurenine synthesis, as analyzed by targeted metabolomic studies on cellular supernatants. We
suggest that inflammatory processes in the brain or periphery could impact on depression by
altering the availability of tryptophan for serotonin synthesis and/or by increasing production of
neurotoxic kynurenine.
K EYWORDS
anti-inflammatory, depression, inflammatory signaling, kynurenine, macrophage, monoaminergic,
transcriptomics, tryptophan
1 INTRODUCTION
Autoimmune and inflammatory diseases are commonly associated
with mood disorders and several lines of evidence indicate inflamma-
tionmay give rise to or exacerbate them.1,2 Studies of animals exposed
to proinflammatory challenges, ranging from LPS administration
Abbreviations: COX, cyclooxygenase; MDD, major depressive disorder; MDMs, monocyte-derivedmacrophages; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressant
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to social defeat, reveal that activation of the peripheral innate immune
system causes a depression-like syndrome of illness behavior: social
withdrawal, reduced mobility/energy, sleep disturbance, weight loss,
and anhedonia.3–5 In humans, IFN𝛼-based therapy for hepatitis C
infection can trigger a major depressive disorder (MDD) resulting in
around 30% of patients withdrawing from treatment.6,7 Conversely,
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TNF𝛼 blockade improves depressive symptoms in patients with
rheumatoid arthritis8 and in a subgroup of patients withMDDand ele-
vated levels of C-reactive protein (an acute phase protein).9
One plausible sequence of events is that peripheral proinflamma-
tory cytokines such asTNF-𝛼, IL-1𝛽 , and IL-6, induced theexpressionof
enzymes involved in tryptophan catabolism, for example, indoleamine
dioxygenase, kynurenine hydroxylase, and kynureninase,10 thereby
reducing the availability of synaptic serotonin11–13;which is a proximal
cause of depressive symptoms.14 Inflammation-induced changes in
tryptophanmetabolism can also lead to increased synthesis of kynure-
nine and its metabolites, many of which are known to be glutamatergic
agonists and/or neurotoxic.15 Thus, inflammation could produce the
“double hit” both reducing the availability of serotonin and increasing
production of kynurenine.
The same mechanisms may explain the clinical observation that
patientswith depressive symptoms in the context of peripheral inflam-
mation (“inflamed depression”) are less responsive to monoaminer-
gic antidepressant drugs, so called “treatment-resistant depression.”16
Selective serotonin reuptake inhibitors (SSRIs), for example, are
thought to increase the synaptic availability of serotonin (by blocking
active uptake by presynaptic neurons expressing the serotonin trans-
porter protein (SERT/SLC6A4)).17 If synaptic serotonin is reduced by
an inflammatory response, and SSRIs are not anti-inflammatory,18
SSRIs are likely to be less effective in the presence of an inflamma-
tory stimulus. Additionally, the neurotoxic effects of kynurenine and
its metabolites, which are exacerbated by inflammation, are medi-
ated by glutamatergic-related mechanisms that are not modulated
by monoaminergic antidepressants. Treatment-resistant depression—
due to reduced serotonin availability and increased neurotoxicity by
non-serotonergic mechanisms—is thus predictable in the context of
peripheral inflammation.12,13,19,20
Here we report on a series of experiments designed to test
the mechanistic connections between inflammatory and monoamin-
ergic systems in a human primary cell model, monocyte-derived
macrophages (MDMs).Macrophages are both initiators andmediators
of inflammation-associatedpathology21 andhave longbeen implicated
in inflammation induced depression,20 largely based on the inflam-
matory induced activation of tryptophan depletion pathways.10,19,20
Microglia, the macrophages of the brain,22 play a crucial role in neu-
ronal homeostasis, and the impairments in neuronal function asso-
ciated with many clinical disorders, including major depression.23
Unlike human macrophages, mouse macrophages do not induce tryp-
tophan uptake or enzymes associated with tryptophan metabolism in
response to proinflammatory signals,24 making them a poor model for
such studies. In the current study, we have used humanMDMs, differ-
entiated by CSF1, to study the impacts of 2 antidepressant drugs and
3 anti-inflammatory drugs on the transcriptional response to 2 proin-
flammatory challenges: LPS and IFN𝛼. In addition to acting as a primary
human cell model for microglia, these cells are also used to examine
tryptophandepletionmechanismsduringperipheral inflammation, and
how drugsmay influence this effect.
LPS is a well-studied Gram-negative bacterial cell wall endotoxin
that acts through activation of the TLR4 receptor, an archetypal pat-
tern recognition receptor that signals through two well-defined com-
plementary signaling pathways to induce proinflammatory cytokines
and IFN target genes.25,26 As part of the FANTOM5 consortium,
we have recently generated extensive promotor-level data on the
time-course of the response of MDM.27 IFN𝛼 is a type-1 IFN and was
chosen as a stimulus because of the clinical data indicating that this
agent can cause a depressive syndrome in patients.6,7 We have previ-
ously compared and contrasted the transcriptional response of mouse
macrophages to type-1 IFN and LPS treatment.28
Three classes of anti-inflammatory drugs were selected to
examine their effects on both inflammatory stimuli: a neutralizing
antibody for the inflammatory cytokine TNF𝛼; a nonsteroidal anti-
inflammatory drug (indomethacin); and a steroidal anti-inflammatory
drug (prednisolone). Neutralizing anti-TNF𝛼 antibodies act by binding
to TNF𝛼 in circulation, thus blocking its proinflammatory effects
mediated by action at TNF receptors.29 TNF𝛼 acts in an autocrine
manner on stimulated macrophages to induce downstream tar-
gets and amplify the initial induction of proinflammatory target
genes.27,30 Indomethacin acts by inhibiting cyclooxygenase (COX) or
prostaglandin synthase enzymes (COX1/COX2; PTGS1/PTGS2).31 The
anti-inflammatory activity of COX inhibitors is thought to depend on
preventing inducible prostaglandin production, which can also act in
an autocrine manner in macrophages through inducible prostaglandin
receptors.25 Both COX-inhibiting and TNF𝛼-inhibiting drugs have
been shown to have some antidepressant and anxiolytic effects in
patients with psychologic symptoms in the context of medical inflam-
matory disorders.32 Synthetic glucocorticoids, such as prednisolone,
are amongst themost commonly prescribed anti-inflammatory agents,
and act by inducing multiple feedback repressors of inflammation,
including I𝜅B and DUSP1.33 The responses to glucocorticoids also
differ radically between humans and mice, due to the gain and loss of
glucocorticoid response elements in enhancers,33 so there is a clear
need to study their effects in humans systems. The glucocorticoid
ligand/receptor complex may also directly repress signaling by inter-
fering with the activation of the inflammatory transcription factor
NF-𝜅B34 leading to a genome wide blockade of NF-𝜅B interactions
with chromatin.35
We also studied the action of two monoaminergic antidepressant
drugs on MDMs, a SSRI (escitalopram) and a tricyclic antidepressant
(TCA; nortriptyline). SSRIs are the most commonly prescribed drugs
for treating depression and their efficacy depends at least partly
on increasing synaptic availability of serotonin (5-HT). However,
5-HT also plays an important role in immune signaling,36 and SSRIs
have been shown to enhance the cytolytic function of NK cells, to
enhance B cell numbers, and to inhibit 5-HT uptake and immune
signaling by dendritic cells,37 suggesting that immune mechanisms
might also contribute to their therapeutic efficacy. The TCAs are less
selectively serotonergic, and also block multiple classes of receptors
for acetylcholine, histamine and noradrenaline. The use of TCAs in the
treatment of the residual symptoms of inflammatory bowel disease,38
suggests they may have some efficacy as anti-inflammatory agents.39
Supplemental Fig. S1 illustrates the knownmode of action of each drug
examined here.
We analyzed the gene expression profiles of MDM in response
to inflammatory challenge in the presence and absence of
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anti-inflammatory or monoaminergic antidepressant drug treatment.
Network-based methods were deployed to represent the expression
changes induced by inflammatory challenges, and the modulation of
response by each of the 5 drugs tested. We tested the specific prior
hypotheses (i) that proinflammatory challenges will cause changes
in expression of genes related to tryptophan metabolism; (ii) that
monoaminergic antidepressants (nortriptyline, escitalopram) will
attenuate inflammation-induced changes in tryptophan-related genes;
or (iii) that anti-inflammatory drugs (prednisolone, indomethacin, anti-
TNF𝛼 antibody) will attenuate the regulation of tryptophan-related
genes; (iv) that inflammatory activation of humanmacrophages results
in decreased production of tryptophan and increased production
of kynurenine; and (v) that anti-inflammatory drugs can attenuate
changes in tryptophanmetabolism and kynurenine production.
2 MATERIALS AND METHODS
2.1 Study design overview
MDM cultures from each of 6 different individuals were treated with
1 of the 3 anti-inflammatory drugs, 2 antidepressant drugs, or a vehi-
cle control. They were then stimulated with either IFN𝛼 or LPS for
either 7 or 24 h prior to sample collection, or incubated for 24 h with
no inflammatory stimulus. Cell culture supernatants were then ana-
lyzed by ELISA for cytokine production, and RNA samples extracted
from cells and subjected to microarray analysis (Fig. 1). Analysis of
these data revealed changes induced by inflammatory challenge in
tryptophan/kynurenine gene expression that weremoderated by anti-
inflammatory drugs and predictive of altered tryptophan/kynurenine
metabolism. We tested this prediction in a secondary metabolomics
study of the effects of inflammatory challenge and drug treatment on
the levels of tryptophan and kynurenine, measured in the cell super-
natant using HPLC/MS. A linear mixed effects model was employed
with each donor/subject as a random effect to account for interdonor
variations, which could potentially lead to false results with a sample
size of only n= 6 (see below).
2.2 Ethics and donors
Human CD14+ mononuclear cells were isolated from fresh blood of
volunteer donors under ethical approval from Lothian Research Ethics
Committee (11/AL/0168).
2.3 Cell culture
Human peripheral blood monocytes were isolated from 320 mL blood
samples by Ficoll gradient separation of buffy coats followed byMACS
CD14+ selection (Miltenyi Biotec Ltd., Bisley, UK). They were then
cultured at 5 × 105 cells/well in 1 mL on a 12-well plate in RPMI sup-
plemented with penicillin/streptomycin, glutamax (Invitrogen, Lough-
borough, UK), and 10% fetal calf serum for 7 d in the presence of
rhCSF-1 (a gift from Chiron, Emeryville, CA) at 104 U/mL to produce
MDM.All donorsweremedically healthy and between 20 and 50 years
old (3male, 3 female).
IFN𝛼 (SRP4594; Sigma–Aldrich, Gillingham, UK) was used at 50
U/mL, within the range reported to be present in blood serum
following IFN𝛼-2b/Ribavirin therapy for hepatitis C patients.40 LPS
from Salmonella enterica serotype minnesota (Re 595, L9764; Sigma–
Aldrich) was used at 10 ng/mL, which is just maximal for inducible
proinflammatory gene expression.28 MDMcultures from each of the 6
individualswere stimulatedwith IFN𝛼 or LPS for7or24h, or incubated
for 24 h with no inflammatory stimulus as a control. Parallel cultures
included 100 𝜇M indomethacin (Sigma–Aldrich), 1 𝜇M prednisolone
(Sigma–Aldrich), 5 𝜇g IgG1 anti-TNF𝛼 antibody (MAB610; R&D Sys-
tems, Wiesbaden, Germany), 100 nM escitalopram (Sigma–Aldrich),
1 𝜇Mnortriptyline (Sigma–Aldrich), or IgG1 isotype control (R&D Sys-
tems, Abingdon, UK) in DMSO at the times indicated (7 or 24 h). Data
supporting the rationale and optimization of inflammatory challenge
and drug doses on cell viability assays are provided in Supplemental
Materials and Methods. We noted that the dose of both monoamin-
ergic drugs (escitalopram and nortriptyline) was limited by their cyto-
toxic effects onMDMs in vitro (Supplemental Fig. S2).
2.4 Optimization of inflammatory stimulation
and drug concentrations
Cell viability was measured to optimize the concentrations of drugs
used (other than anti-TNF𝛼). This was performed using CellTiter-Glo
(Promega Ltd., Southampton,UK) according tomanufacturer’s instruc-
tions. Briefly, cells were seeded at 1 × 105 cells/well in 96-well, flat-
bottomed white-walled plates (Corning Ltd., Wiesbaden, Germany)
and cultured in 100 𝜇L media. Following maturation and consequent
drug treatment, 100 𝜇L CellTiter-Glo was added to each well (1:1
ratio) and the plate was placed on a shaker for 10 min. Luminescence
wasmeasured in technical triplicates using a GloMax R©96-Microplate
Luminometer (Promega) and percentage of viable cells after each
treatment was calculated relative to the untreated control culture.
Six biologic replicates were used to test escitalopram (SSRI) and nor-
triptyline (TCA), 3 for indomethacin and prednisolone. Supplemen-
tal Figs. S2A and B display the cell viability in the presence of esci-
talopram or nortriptyline at 24 h post-treatment. To ensure maximal
drug contact with the cells without affecting viability, concentrations
of 100 nM for nortriptyline and 1 𝜇M for escitalopram were selected
for the transcriptomics studies. These concentrations are higher than
peak whole blood concentrations of escitalopram (∼0.1 nM41) or nor-
triptyline (50 nM42) in patients. Supplemental Figs. S2C and D show
cell viability was not significantly affected by any of the tested con-
centrations of indomethacin or prednisolone. We therefore selected
concentrations of 100 𝜇M indomethacin and 1 𝜇M prednisolone, as
used in previous in vitro studies of macrophages.43,44 The amount
of anti-TNF𝛼 antibody used was calculated to be 5 𝜇g/mL. This was
based on the suppliers ND50 value of 0.01–0.04 𝜇g/mL in the presence
of 0.75 ng/mL TNF𝛼 and our own measurements of maximum TNF𝛼
production from stimulated macrophages (<30 ng/mL). We then used
the following equation to calculate the amount of antibody required:
KD =
[mAb][ Target]
[Complex] .
IFN𝛼 (SRP4594, Sigma–Aldrich) was supplemented at 50 U/mL
as this concentration yields a robust inflammatory response in
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F IGURE 1 Study design and differential gene expression in response to inflammatory challenge. (A) Schematic representation of experimental
design. Fully differentiated humanMDMs (day 8) were generated from 6 individuals aged 20–30 years, 3 male and 3 female. Cells were then pre-
treated with either escitalopram, nortriptyline, an anti-TNF𝛼 antibody, indomethacin, prednisolone, or controls (a nonspecific IgG antibody with
DMSO vector), or untreated. Cells were then exposed to LPS or IFN𝛼 challenge and harvested at either 7 or 24 h, or cultured for 24 h with no
inflammatory stimulus. (B) Numbers of significantly differentially expressed genes (DEGs) following inflammatory stimulation (P< 0.001). (C) Venn
diagrams displaying the overlap of DEGs between IFN𝛼 and LPS challenges at early or late time points
macrophages and is within the range reported to be present in blood
serum following IFN𝛼-2b/Ribavirin therapy for hepatitis C patients.40
Althoughmany in vitro studies typically use 100 ng/mL of LPS, we used
10 ng/mL in order to consistently stimulate the cells for 24 h without
obscuring any of the subtler downstream signaling effects (LPS from S.
enterica serotypeminnesota Re 595, L9764; Sigma–Aldrich).
The final parameters for the experiment involving MDM, inflam-
matory stimuli and drug treatments are outlined in Supplemen-
tal Fig. 1A. Each of the MDM cultures from 6 different individu-
als were treated separately with each of the 3 anti-inflammatory
drugs, 2 antidepressants, vehicle control, or left untreated. Sam-
ples were then stimulated with either IFN𝛼 or LPS for either 7
or 24 h, or incubated for 24 h with no inflammatory stimulus as
a control. RNA was extracted from the samples and analyzed by
expressionmicroarray
2.5 RNA extraction and processing
RNA was prepared using RNeasy column-based extraction (Qiagen,
Manchester, UK). 350 𝜇L of RNeasy buffer RLT was used per sample
to extract RNA, which was eluted from the column in water following
on-column DNase treatment. RNA quality was subsequently analyzed
using a 2200 Tapestation (Agilent, Edinburgh, UK). For expression
microarrays, 500 ng of RNA was prepared using standard Affymetrix
protocols and applied to the Human Gene 2.1 ST array by Edinburgh
Genomics (Edinburgh, UK).
2.6 Expression data analysis
Analysis was performed using R/Bioconductor packages “array-
QualityMetrics,”45 “oligo,”46 and “nlme.”47 Normalization was
performed using RMA.48 Probesets were collapsed down to a sin-
gle gene. These data are available on Gene Expression Omnibus
(GEOGSE85333).
Differentially expressed genes (DEGs) at each of the post-
inflammatory challenge time points (LPS or IFN at 7 or 24 h) were
first estimated by a linear mixed effects model with inflammatory
challenge as a fixed effect and donor (participant) as a random effect.
To test the hypothesis that drug treatment significantly modulated
the genomic response to inflammatory challenge, we extended the
linearmixed effects model to include both inflammatory challenge and
drug treatment as fixed effects, the interaction between challenge
and drug as a fixed effect, and donor as a random effect. This model
was fit to data from the second (24 h) post-inflammatory time point.
Tests for significance of all linear model coefficients are reported at
uncorrected false-positive rates of P < 0.05, P < 0.01, and P < 0.001
as indicated.
Network analysis was performed using Graphia Professional soft-
ware (Kajeka Ltd., Edinburgh, UK) to explore inflammation- and drug-
related transcriptional changes in the context of the transcriptome.
Reactome software was used49 for enrichment analysis of DEGs pre-
viously implicated in neuronal signaling or depression.
2.7 Quantitation of selected neurotransmitter
metabolites
To confirm the predicted metabolic effects of these treatments on the
expression of genes related to tryptophanmetabolism, tryptophan and
kynurenine concentrations were measured by HPLC/MS in the super-
natant of cells after 24 h incubation (Supplemental Materials).
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2.8 Quantitation of cytokine production in sample
supernatants
To compare protein production to transcript levels, cytokine pro-
duction was measured in the supernatant of cells by use of TNF-
𝛼 (#KAC1751) and IL-6 (#KHC0061C) ELISA kits (ThermoFisher,
Runcorn, UK). Precoated plates were used according to manufac-
turer’s instructions. Briefly, plates were blocked for nonspecific bind-
ing. Supernatants, or standard controls, were then allowed to bind
to the precoated antibodies before washing and addition of a sec-
ondary HRP-conjugated antibody. Absorbance was read at 450 nm
by a plate reader and cytokine concentration was calculated from the
standard curve.
3 RESULTS
3.1 Transcriptional regulation inMDMby LPS
and IFN𝜶
LPS significantly modulated the expression of 3294 genes and IFN𝛼
challenge 743 genes in human MDM, consistent with previous
observations.24,27,50 Both challenges showed the greatest effect at
7 h (Fig. 1 and Supplemental Table S1). As previously observed in
mouse macrophages,28 IFN𝛼 responsive genes were largely a subset
of the LPS response: approximately 2 out of 3 of the IFN𝛼 respon-
sive genes were also differentially expressed following LPS treatment.
A sample-to-sample correlation network (Fig. 2) demonstrated that
samples grouped together according to stimulus. Notably, the 7 h LPS
samples were most distant (least correlated with) from the control
samples. In keeping with evidence that LPS-inducible genes in mono-
cytes can be treated as quantitative traits with extensive variation
between individuals,51 samples from the same donor tended to be in
the same neighborhood.
A network model of the transcriptional network was constructed
in which each of 3034 nodes represent a DEG and the edges connect-
ing nodes represented a strong positive correlation (r> 0.93) between
gene expression profiles across all the samples in the dataset (Fig. 2C).
Genes with a similar expression profile tended to group closely
together. Regulated genes grouped into9major clusters of strongly co-
expressed genes: 4 clusters of genes thatwereup-regulated and5 clus-
ters of down-regulated genes (Fig. 2D).
3.2 Effects of monoaminergic antidepressant drugs
onwhole transcriptome
At the nontoxic doses used in this study, neither antidepressant drug
had a significant effect on the macrophage response to either LPS or
IFN𝛼 (Supplemental Fig. S3).
3.3 Effects of anti-inflammatory drugs onwhole
transcriptome
Consistent with their different modes of action, each of the anti-
inflammatory drugs influenced the response to LPS or IFN𝛼 in a
distinct manner. For example, each drug had a specific effect on the
transcription profile of 3 classical inflammatory genes (IL1B, IL6, and
TNF) induced by LPS or IFN𝛼 challenge (Figs. 3A–F). These data were
confirmed at the protein level as measurement of the corresponding
cytokine in the supernatants of these same samples (Supplemental Fig.
S4) reflected patterns observed at the gene level. A complete list of
theDEGs associatedwith the responses to the two inflammatory stim-
uli, and the effect of each drug treatment is provided in Supplemental
Table S2 and Fig. 3G, respectively. The Venn diagrams (Figs. 3H and I)
further illustrate how each drug affected the inflammatory response
in a unique manner. Drug modulated genes were visualized in the con-
text of the gene network as a whole (Figs. 3J–L), demonstrating pred-
nisolone and the anti-TNF antibody act predominantly by reducing the
expression of genes that were up-regulated, or increasing the expres-
sion of genes that were down-regulated by the proinflammatory stim-
uli. Enrichment analysis confirmed that the genes regulated by LPS or
IFN𝛼, and modulated by drug treatment, were functionally important
for immune signaling and related to the mechanisms of drug action;
see Supplemental Table S1 for a summary and Supplemental Table S3
for details. The effect of indomethacin was more complex than simply
inhibiting the responses to LPS and IFN𝛼, consistent with the known
ability to prevent expression of prostaglandins, which act as feedback
inhibitors of gene expression.52 In many cases, it appeared to further
elevate the expression of genes already up- or down-regulated, partic-
ularly those associated with lipidmetabolism.
3.4 Regulated expression of genes involved
in tryptophanmetabolism
Amongst the many genes that demonstrated a significant interaction
between the two inflammatory stimuli and drug treatment, we focused
on pathways for tryptophan catabolism and transport. This pathway
relates to the prior hypothesis that tryptophan metabolism could be a
key mechanism linking peripheral inflammation to depression.10,20,53
A schematic representation of this metabolic pathway is illustrated
in Fig. 4.
Both LPS and IFN𝛼 caused significant changes in the expression
of genes encoding enzyme or transporter proteins that play crucial
roles in the metabolism of tryptophan. LPS caused a pronounced up-
regulation of genes encoding 2 tryptophan transporters (SLC16A10
and SLC7A5), and up-regulation of genes coding enzymes on the
pathway to kynurenine and its metabolites (IDO1, KYNU, and KMO).
LPS also caused significant down-regulation of genes coding kynure-
nine metabolic enzymes (AFMID and CCBL7). Other tryptophan trans-
porters in human macrophages, the heavy chain Y+L SLC3A2 (CD98)
and SLC7A7 are expressed constitutively at high levels.27 IFN𝛼 chal-
lenge resulted in a similar profile of effects on the expression of genes
encoding the kynurenine metabolic enzymes, but did not produce sig-
nificant elevation of the tryptophan transporter genes (Fig. 4).
Anti-inflammatory drugs significantly modulated the on the
inducible expression of genes encoding serotonin transporters and
kynurenine metabolic enzymes. Interestingly, the direction of change
in gene expression caused by anti-inflammatory drug treatment was
always opposite in sign to the change caused by activating stimulus.
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F IGURE 2 Network analysis of the effects of inflammatory challenge and drug treatment on the transcriptome. Sample-sample correlation
network constructed from the normalized microarray dataset colored according to (A) inflammatory stimulus or (B) by donor. Nodes represent
samples within the dataset and edges represent correlations between samples greater than the threshold (r > 0.96). Samples closer to each other
are more similar (highly correlated). Separation of the samples is observed by inflammatory stimulus and by donor. (C) A gene–gene correlation
network constructed from DEGs from the microarray dataset (r > 0.93). Nodes represent genes which cluster together based on their pattern
of expression. (D) Mean signal intensity of the genes in 9 of the largest clusters are displayed on the right with GO functional enrichment terms
(numbered in order of size)
In other words, 4 of the 5 genes that were up-regulated in response
to challenge (SLC16A10, SLC7A5, IDO1, and KYNU), were less strongly
induced after drug treatments; and all 3 genes that were down-
regulated in response to challenge (SLC7A8, AFMID, and CCBL7) were
less strongly repressed (Fig. 4).
Thus, all anti-inflammatory drugs tested were found to impact
tryptophan- or kynurenine-related gene expression. Indomethacin
had effects mainly on tryptophan transporter genes; prednisolone on
kynureninemetabolism genes; and anti-TNF𝛼 on both class of genes.
3.5 Effects of macrophage activators (LPS, IFN𝜶)
and drugs on tryptophan-relatedmetabolite
concentrations
In keeping with the gene expression data, LPS treatment led to
70–80% depletion of tryptophan in the medium and accumulation
of kynurenine. IFN𝛼 exerted a similar effect, but the magnitude of
change in these metabolites was less. Of the three anti-inflammatory
drugs tested, only indomethacin significantly attenuated LPS-induced
reduction in tryptophan availability (Fig. 5). Both anti-TNF𝛼 and
indomethacin significantly reduced kynurenine production to ∼70%
and ∼50% following IFN𝛼 stimulation but did not reduce kynure-
nine following LPS treatment (Fig. 5). The kynurenine to tryptophan
(Kyn/Trp) ratio was used as a measure of tryptophan catabolism over-
all (Fig. 5). Anti-TNF𝛼 treatment significantlymoderated IFN𝛼-induced
increases in Kyn/Trp (P= 0.018); and indomethacin treatment likewise
significantly moderated LPS-induced increases in the ratio of kynure-
nine to tryptophan (P= 0.026).
4 DISCUSSION
Evidence for a link between systemic inflammatory disease
and depression (or depressive behavior in animals3,5) is now
overwhelming.2 We investigated the effects of LPS or IFN𝛼 chal-
lenge on gene expression by CSF1-cultured MDMs. The scale of the
transcriptional response to LPS and IFN𝛼 in these data was compa-
rable to previous studies. LPS is itself known to induce type 1 IFNs
(mainly IFN𝛽) in MDM, which act in an autocrine manner via IFNAR1,
itself induced by LPS.27 Accordingly, the response to exogenous type
1 IFN (IFN𝛼) was largely a subset of the LPS response, as reported in
previous studies.24,28,50,51,54 None of the anti-inflammatory agents
we examined completely prevented the response to either challenge
and, although prednisolone and anti-TNF𝛼 both reduced expression
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F IGURE 3 Anti-inflammatory drug effects on inflammation-induced gene expression.The expression intensity of IL1𝛽 (A, D), IL6 (B, E), and TNF
(C, F) are displayed following treatment with anti-inflammatory drugs or vehicle control and LPS (A–C) or IFN𝛼 (D–F) challenge. The numbers of
genesdifferentially expressedby the interactionof anti-inflammatorydrug treatment andproinflammatory challenge, and their directionof change
when compared with control-treated samples, are displayed in a table (G) and as Venn diagrams for each drug (H, I). These DEGs were overlaid on
the gene–gene correlation network from Fig. 2: red = genes overexpressed by drug treatment, blue = genes underexpressed by drug treatment.
Genes significantly modulated by anti-TNF𝛼 treatment (J), indomethacin treatment (K), and prednisolone treatment (L) are displayed separately.
of many genes that were up- or down-regulated by the inflammatory
challenges, each had a distinctive transcriptional effect. This diversity
likely reflects the complex feed-forward and negative feedback loops
that characterize the response to LPS27,55 and the different mode of
action of each drug.
Both stimuli greatly increased expression (∼3000 fold following
LPS) of the gene encoding the enzyme indoleamine 2,3-dioxygenase
(IDO1). IDO1 catalyzes the primary reaction in conversion of tryp-
tophan to kynurenine; thereby reducing its availability as a pre-
cursor for serotonin metabolism. While this process has been
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F IGURE 4 Effects of proinflammatory challenge and anti-inflammatory drugs on expression of genes related to tryptophan and kynurenine
metabolism. The pathway model summarizes the metabolic role of 8 proteins involved in tryptophan transport or catabolism as illustrated. The
profile of expression changes for each gene following proinflammatory challenge is shown by the line graphs during each drug treatment. Signifi-
cance is depicted for every significant interaction of anti-inflammatory drug treatment with proinflammatory challenge, and color coded for each
drug treatment. *P< 0.05, **P< 0.01
associated with immunosuppression through Treg activation and
effector T cell suppression,56 inflammation-induced expression of this
enzyme leads to tryptophan depletion both locally and systemically in
chronic inflammatory states and has also been linked to alterations in
mood.5,53,57 Similarly, the ability of host microbiota to control trypto-
phan metabolism has been functionally linked to influencing mood.58
Furthermore, polymorphisms in IDO1 have been associated with sus-
ceptibility to IFN𝛼-induced depression in hepatitis patients.59 This
may arise both from the depletion of tryptophan, and the generation
of neurotoxic metabolites such as kynurenine.5,60 However, trypto-
phan depletion in depressed patients was reportedly independent of
kynurenine pathway activation.61
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F IGURE 5 Metabolomic analysis of effects of inflammatory challenge and anti-inflammatory drug treatment on tryptophan concentration
and tryptophan/kynurenine concentration ratio. Tryptophan (A) and kynurenine (B) concentrations in cell culture supernatants 24 h after pre-
treatment of the 3 anti-inflammatory drugs before each inflammatory challenge. (C) Ratio of kynurenine to tryptophan levels detected in the
supernatant. Significance was calculated using a ratio paired t test. *P< 0.05 **P< 0.001
Anti-TNF𝛼 reduced transcription of tryptophan catabolism
enzymes, IDO1 and KYNU, following IFN𝛼 stimulation but no signifi-
cant effect of the drug was observed on these elements following LPS
treatment. This is likely due to the transient induction of feed-forward
and negative feedback loops of TNF𝛼 transcription following inflam-
matory stimulus. Like IFN𝛼, TNF𝛼 was predicted to be involved in an
autocrine loop in MDM elicited by LPS, since the TNF𝛼 receptor is
also induced.27 Our data (Supplemental Table S2) confirm and extend
evidence of autocrine TNF𝛼 signaling as a feed-forward activator
of macrophage gene expression30,62,63 and identify the subset of
inducible genes dependent upon that stimulus. The lack of impact
of anti-TNF𝛼 on LPS-inducible IDO1 may reflect the magnitude of
the response. Alternatively, activation of IDO1 by IFN-𝛾 requires
co-stimulation by TNF𝛼, which increases the occupancy of IFN-
response elements.64,65 It may be that LPS provides this second signal
independently of TNF𝛼.30,62,63
A study examining the treatment of primary murine hippocampal
cells with ibuprofen, a nonselective COX inhibitor like indomethacin,
identifiedTDO2as themost significantly affectedgene.66 TDO2,which
is not expressed in macrophages, acts like IDO1 to metabolize tryp-
tophan to kynurenic metabolites. However, although anti-TNF𝛼 and
prednisolone each significantly reduced IDO1 activity at 24 h post-
IFN𝛼 stimulation, indomethacin treatment did not. Indomethacin did,
however, significantly reduce transcription of tryptophan transporters
induced by both inflammatory challenges, potentially reducing the
availability of intracellular tryptophan as a substrate for IDO1. In
contrast, anti-TNF𝛼 treatment reduced transcription of one trypto-
phan transporter while increasing transcription of another during LPS
challenge, and prednisolone did not affect the mRNA levels of any
transporter.
To directly assess tryptophan uptake and catabolism follow-
ing each treatment, we measured the concentrations of trypto-
phan and kynurenine in the supernatant. Indomethacin was the
only inhibitor that impacted tryptophan levels during LPS chal-
lenge, likely due to a transcription repression of the tryptophan
transporter. Prednisolone, while modulating expression of numer-
ous inducible genes, did not produce any alteration in overall tryp-
tophan catabolism (Supplemental Fig. S5), despite reducing expres-
sion of tryptophan catabolism-related genes such as IDO1, KYNU,
and CCBL1.
A recent review examined the anti-inflammatory effects of
antidepressant drugs.67 We found no evidence that either of the
monoaminergic antidepressant drugs tested (TCAor SSRI) exerted any
effect on the response in MDMs to LPS or IFN𝛼. This is in contrast to
reports that TCAs reduce proinflammatory signaling in phagocytes,68
and SSRIs have been reported to alter macrophage differentiation
and inflammatory signaling.67,69 SSRIs have also been reported to
modulate glucocorticoid actions on monocytes.70 Although we found
no direct effect of SSRIs or TCAs on macrophage responses to either
LPS or IFN𝛼, we did observe significant cytotoxicity at concentrations
that were <20-fold lower than circulating blood concentrations
in treated patients. In support of this, nortriptyline has previously
been shown to induce autophagy in macrophages.39 Indeed, many
antidepressants are cationic amphipaths, and are therefore
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lysosomotropic71 likely accumulating selectively in phagocytic cells.
Selective toxicity to macrophages may therefore contribute to the
results reported in other studies, which used far higher concentrations
of SSRIs than used here.69
There is already some evidence that anti-inflammatory drugs
can have antidepressant efficacy.32 Our results are compatible with
the mechanistic interpretation that this may be at least partly
attributable to the effects of anti-inflammatory drugs on “normaliza-
tion” of an inflammation-induced bias in tryptophan and kynurenine
metabolism. However, the results also indicate that this is unlikely
to be the sole mechanism, and each agent may produce distinct
patterns of regulation of genes that can impact indirectly on neu-
ronal function expression. If each anti-inflammatory agent is dis-
tinct in its actions, it may be that combinations would have novel
potential efficacy.
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